정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
170 | Recruiting | To Evaluate the Safety and Efficacy of CT-P59 in Patients With Mild to Moderate Syptoms of Severe Acute Respiratory Syndrome COVID-19 | SARS-CoV-2 Infection | Biological: CT-P59/Placebo | Phase 3 | Celltrion | INDUSTRY | 1020 | All | 18 Years | Chungnam National University Hospital, Daejeon, Jung-gu, Korea, Republic of |
169 | Recruiting | To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants | Covid19 | Drug: TQ Formula/Tab | Phase 2 | Novatek Pharmaceuticals | INDUSTRY | 60 | All | 18 Years | Respire Research, San Diego, California, United States L & A Morales Healthcare, Hialeah, Florida, United States United Memorial Medical Center, Houston, Texas, United States |
168 | Recruiting | To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults | Coronavirus Disease (COVID-19) | Biological: CoVepiT (OSE13E) | Phase 1 | OSE Immunotherapeutics | INDUSTRY | 48 | All | 18 Years ~ 45 Years | Center for Vaccinology (CEVAC),, Gent, Belgium |
167 | Not yet recruiting | To Evaluate the Safety, Tolerability and Pharmacokinetic Properties of DWRX2003 | COVID-19 Patients | Drug: DWRX2003 | Phase 1 | Daewoong Pharmaceutical Co. LTD., Novotech (Australia) Pty Limited | INDUSTRY | 24 | All | 18 Years ~ 65 Years | |
166 | Recruiting | To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects | SARS-CoV-2 Infection | Drug: CT-P59 Drug: Placebo |
Phase 1 | Celltrion | INDUSTRY | 32 | All | 19 Years ~ 55 Years | Chungnam National University Hospital, Daejeon, Korea, Republic of |
165 | Not yet recruiting | To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects | SARS-CoV-2 Infection | Drug: CT-P63 Drug: Placebo |
Phase 1 | Celltrion | INDUSTRY | 24 | All | 18 Years ~ 60 Years | Biokinetica S.A, Jozefow, Poland |
164 | Completed | TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience | Covid19 | Drug: Tocilizumab | Phase 4 | FMH College of Medicine and Dentistry | OTHER | 93 | All | 16 Years ~ 85 Years | Fatima Memorial Hospital College of Medicine & Dentistry, Lahore, Punjab, Pakistan |